Centanafadine emerges as a triple-action ADHD treatment with potential for patients with anxiety

A new ADHD medication, centanafadine, stands out as the first to simultaneously target dopamine, norepinephrine, and serotonin, offering a novel approach that may benefit patients unresponsive to existing treatments, with ongoing assessments of its safety and regulatory status worldwide.

Centanafadine, marketed as Simtriyo, is being positioned as a new option for attention-deficit/hyperactivity disorder, with researchers describing it as the first ADHD medicine to act on dopamine, norepinephrine and serotonin at the same time. That sets it apart from many existing treatments, which typically focus on just dopamine and norepinephrine, and helps explain why clinicians are watching it closely as another tool for patients who do not respond well to current medicines. PubMed and other drug references describe it as a norepinephrine, dopamine and serotonin reuptake inhibitor, while Otsuka has recently reported further late-stage data in adults with ADHD and anxiety.

The medicine’s main idea is straightforward: by slowing the brain’s reuptake of those neurotransmitters, it leaves more of them available for communication between nerve cells. In practice, that may help with inattention, impulsivity and hyperactivity. The key difference from many stimulants, such as methylphenidate and lisdexamfetamine, is the added effect on serotonin. That does not make centanafadine an antidepressant, but it does make it unusual among ADHD treatments and has fuelled interest in whether it may have a role in people who also live with anxiety or depression.

Evidence so far suggests it works, at least better than placebo. A PubMed-indexed report on two phase 3 adult trials found significant symptom improvement with 200 mg and 400 mg doses, and a separate study in adolescents also showed meaningful benefits against placebo. A 52-week safety study in adults found it was generally well tolerated. Still, the studies have not yet produced direct head-to-head comparisons with established drugs, so it is too soon to say whether centanafadine is more effective than the medicines already in use.

The side effects reported most often include reduced appetite, insomnia, dry mouth and headache, which overlap with the effects seen with other ADHD treatments. Product information also carries a warning about suicidal thoughts and behaviour, a standard precaution for several medicines used in ADHD and depression. One point that remains unclear is its regulatory status: the MedicalXpress article says it has been approved in the United States for adults and children aged 6 and older, but other drug-tracking sources still describe it as under development and not yet approved by the US Food and Drug Administration. It is also not yet approved by Australia’s Therapeutic Goods Administration, so access there remains limited for now.